This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon

Weight management

Retatrutide

The third generation of incretin research: a triple agonist that combines GLP-1, GIP and glucagon in one molecule.

5 min read 4 sources Calculator Titration Updated May 2026
Class
Triple agonist (GLP-1 / GIP / glucagon)
Frequency
Once weekly (subcutaneous)
Half-life
~6 days
Form
Lyophilised powder, reconstituted with BAC water

Members only

Dosing recommendations are visible to logged-in members only. Logging in is free.

Log in / sign up

Equipment

Equipment you need

For reconstitution and injection you need a bit of basic gear. Here are solid, cheap options:

As an Amazon associate we earn from qualifying purchases. Links open Amazon - no extra cost for you.

Getting started

Titration schedule for getting started

This eases you in. It is not a plan you have to work through, more on that under dosing.

Members only

Dosing recommendations are visible to logged-in members only. Logging in is free.

Log in / sign up

What is Retatrutide?

Retatrutide (development name LY3437943) is the third generation of incretin research. Where semaglutide hits one receptor and Tirzepatide two, Retatrutide acts on three at once: GLP-1, GIP and additionally glucagon. That third path, the glucagon receptor, is what is new about it and the reason Retatrutide is regarded, in research, as the most potent member of the class so far.

It is injected once a week and the half-life sits at roughly six days. Like the others it comes as a freeze-dried powder you dissolve in bacteriostatic water before the first use.

How it works

You know GLP-1 and GIP from Tirzepatide: they boost the insulin response, slow gastric emptying and dampen appetite. The glucagon receptor is the new addition in Retatrutide. Glucagon sounds counterintuitive at first because it can raise blood sugar, but in concert with the other two paths it mainly increases energy expenditure and fat breakdown, especially in the liver.

In studies this liver effect was particularly clear: liver fat dropped by over 80 percent at the higher doses. Studies suggest the three-path combination moves more on weight and metabolism than the earlier one- or two-receptor approaches.

What you need

Before you start, have everything ready. The list is short:

  • The Retatrutide vial with the freeze-dried powder
  • Bacteriostatic water to dissolve it
  • U-100 insulin syringes for the injection (they also work for drawing the water, you just draw more often; a larger syringe is faster but not a must)
  • Alcohol swabs for the vial cap and the skin
  • A sealable sharps container for used needles

With everything clean and in one place, the rest is straightforward.

Reconstitution

The powder is dissolved in bacteriostatic water. How much water you add sets the concentration, and with it how many units you later draw on the insulin syringe for your dose.

Use the calculator above for exactly this: pick your vial size and the water volume, and you instantly see the concentration and the units per dose. Roughly: less water means higher concentration and fewer units. For large vials from 30mg up, more water is worth it, otherwise the dose gets tiny and hard to read.

When dissolving, just add the bac water and let the powder dissolve. It does not matter if the water hits the powder directly, and swirling or shaking are both fine.

Injection

The injection is subcutaneous, into the fat layer under the skin. Common spots are the abdomen (keep about two finger-widths clear of the navel), the front of the thigh, or the back of the upper arm.

The short version:

  • Clean the spot with an alcohol swab and let it dry
  • Pinch up a small fold of skin
  • Insert the needle at a 45 to 90 degree angle
  • Inject slowly, wait a moment, then withdraw
  • Put the needle straight into the sharps container

Rotate the site each time so the tissue does not get irritated. Never the same spot twice in a row.

Dosing

Members only

Dosing recommendations are visible to logged-in members only. Logging in is free.

Log in / sign up

What the research shows

Retatrutide is still in the middle of clinical research, with the phase 3 programme (TRIUMPH) ongoing. The phase 2 data were clear, though. In the obesity study the highest dose (12mg) led to roughly 24 percent weight reduction at 48 weeks, the strongest figure in the incretin class so far. In people with type 2 diabetes, blood sugar (HbA1c) and weight dropped clearly too, and in a liver substudy liver fat fell by over 80 percent at the higher doses.

The individual studies with links are in the source block below.

Side effects

Like the other incretins, the most common effects are gastrointestinal: nausea, fullness, sometimes diarrhoea or constipation, mainly at the start and after each dose increase. Through the glucagon path, studies additionally noted a slight rise in heart rate. Both are dose-dependent and one more reason to ease in slowly and not go up too fast.

Lifestyle

Retatrutide takes the hunger away, the rest is on you. A few things get more out of the research phase and keep you healthy:

  • Enough protein. If you eat little, make the little you eat protein-rich, or you lose muscle along with fat.
  • Drink enough. With low appetite you often drink less without noticing, and the risk of dehydration goes up.
  • Resistance training. Keeps muscle mass while the weight comes off.
  • Eat slowly. With delayed gastric emptying you fill up faster, big portions sit heavy.

Alcohol and very fatty meals make the nausea noticeably worse, especially early on.

Storage

The undissolved powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. Once dissolved, the solution goes into the fridge (2 to 8 degrees) and stays stable there for at least 8 to 10 weeks with barely any loss of potency, in practice considerably longer. The bacteriostatic water brings a preservative that keeps the dissolved form stable for longer.

Evidence

Sources

  1. 1 Phase 2 study in obesity (up to ~24% weight reduction at 48 weeks). Jastreboff et al., New England Journal of Medicine, 2023
  2. 2 Phase 2 study in type 2 diabetes. Rosenstock et al., The Lancet, 2023
  3. 3 Phase 2a study on liver fat (MASLD, over 80% reduction at the higher doses). Sanyal et al., Nature Medicine, 2024
  4. 4 Discovery and pharmacology of the triple agonist (preclinical). Coskun et al., Cell Metabolism, 2022

Keep reading

More in the lexicon

In the shop

Retatrutide in the catalog

Sizes, prices and availability for research use. Straight from the lexicon to the product page.

View in shop